Basic Information of Retatrutide
- CAS 2381089-83-2
- Purity: >99%
- Molecular formula: C221H342N46O68
- Molecular weight: 4731.35
Introduction of Retatrutide
Retatrutide is a new type of hypoglycemic and weight-loss drug that works by stimulating GIP, GLP-1 and GCG3 receptors
Scientific experimental studies have shown that weekly injections of Retatrutide (12 mg) can reduce the average weight of patients by 24.2% after 48 weeks, which is the best effect that drug weight loss can achieve so far.
With weekly injections of Retatrutide (12 mg), all patients can achieve a weight loss of >5%; nearly half of the patients can achieve a weight loss of ≥25%; and 1/4 of the patients can achieve a weight loss of ≥30%.
When the weekly injection dose is 8 mg, all patients can achieve a weight loss of >5% after 48 weeks regardless of the dose.
Benefits of Retatrutide
Glycemic reductionFor patients with hyperglycemia, blood sugar can be clearly lowered after taking the medication according to the course of treatment.
Weight lossAn average weight loss of 11-15% can be achieved with the medication according to the course of treatment.
Cardiovascular benefitsRetatrutide can continuously improve all lipid levels except HDL (TG reduced by 40%; LDL reduced by 22%), and has obvious benefits for patients’ diastolic and systolic blood pressure.
Telportide vs Retatrutide
Both are hormones closely related to blood sugar levels.
There are three targets for hypoglycemic and weight-loss drugs, among which GLP-1 and GIP are incretins that promote insulin secretion, while causing satiety and reducing appetite, and GCG can induce energy consumption and increase lipid metabolism.
Telportide is a drug that acts on both GLP-1R/GIPR targets.
Retatrutide is a hypoglycemic and weight-loss drug that targets GLP-1R/GIPR/GCGR3 targets. It adds GCG to the dual-target GLP-1/GIP, and has a better hypoglycemic and weight-loss effect
